Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial

INTERVENTION: Experimental group:Intravenous drip, 0.2 g (4 vials) once daily for adults; slow drip after dilution with 250 ml of 5% Glucose Injection or 0.9% Sodium Chloride Injection, not less than 120 minutes or 30‐40 drops/minute. Continuous administration for 7 days, observation until 21 days or discharge;Control group:Conventional treatment, no control drug; CONDITION: Novel Coronavirus Pneumonia (COVID‐19) PRIMARY OUTCOME: Real‐time fluorescent RT‐PCR detection of pharyngeal swab were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested after the end of medication) and the negative conversion time(measured every other day after the start of medication, determined according to clinical needs);Time to clinical improvement;Change in size of lesion area by chest CT;Time to fever subsidence, defined as the time at which a subject with fever at enrollment has returned to normal temperature for at least 72 hours; SECONDARY OUTCOME: Time to Clinical recovery;Proportion of cases with disease progression;Cough disappearance rate and time;All‐cause mortality;Changes of cytokines (IL‐2, IL‐4, IL‐6, IL‐10, IL‐17, INF‐gama, TNF‐alpha);Markers of immune function: CD4 + and CD8 + T cell counts; INCLUSION CRITERIA: (1) Aged 18 years or older, male or female; (2) Real‐time fluorescent RT‐PCR of pharyngeal swab samples was positive for novel coronavirus nucleic acid; (3) Clinical classification is common or severe; (4) Signed informed consent.